Take a fresh look at your lifestyle.

WHO approval accelerates COVAXIN’s global access and availability: Bharat Biotech Chairman

Bharat Biotech Chairman and Managing Director Dr. Krishna Ella said, the validation by WHO is a very significant step towards ensuring global access to India’s widely administered, safe, and efficacious Covaxin and will facilitate countries to expedite their regulatory approval processes to introduce and administer India’s indigenously made COVID-19 vaccine developed and manufactured by Bharat Biotech.

After getting nod from the WHO, in a statement in Hyderabad, Dr Krishna Ella said, it will also enable the procurement by UNICEF, Pan-American Health Organization (PAHO) and the GAVI COVAX facility for distribution to countries in need.

He further said as an organization, they have focused on maintaining stringent quality and safety standards that meet rigorous assessment, and scientific standards established by WHO.

Midle of the post

He added that the EUL authorisation for Covaxin will enable them to contribute to accelerating the equitable access of COVID-19 vaccine and the access to it globally thereby addressing the current public health emergency.

The Covaxin is a whole virion-inactivated vaccine against SARS-CoV2, developed in partnership with ICMR and NIV, Pune.

Joint Managing Director of Bharat Biotech Mrs. Suchitra Ella said the WHO nod for Covaxin is a validation of the tremendous efforts made by everyone at Bharat Biotech and their partners. She said it is also an opportunity for them to create a meaningful impact at a global level.

Leave A Reply

Your email address will not be published.